Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

This study is looking into new ways to treat advanced breast cancer that has spread to other parts of the body. This specific type of breast cancer is called ER+/HER2- (oestrogen receptor positive/human epidermal growth factor receptor 2 negative). This means the cancer cells grow in response to the hormone oestrogen, but they don't have too much of a protein called HER2.

The main focus is a new drug called elacestrant, which is being tested in combination with several other established breast cancer drugs like alpelisib, everolimus, ribociclib, palbociclib, capivasertib, and abemaciclib. The study is divided into two main stages. The first stage, called Phase 1b, is about finding the best and safest dose of elacestrant when it's given with each of these other drugs. Researchers will closely watch for any side effects at different doses to make sure the combination is well-tolerated.

Once the best doses are found, the second stage, called Phase 2, will involve more people. In this stage, the researchers will check how well these drug combinations work together to slow down or shrink the cancer, and they will continue to monitor their safety. By testing these combinations, the study hopes to find more effective treatments for people living with this type of advanced breast cancer.